TY - JOUR
T1 - Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease
AU - Van Der Walt, Joelle M.
AU - Noureddine, Maher A.
AU - Kittappa, Raja
AU - Hauser, Michael A.
AU - Scott, William K.
AU - McKay, Ron
AU - Zhang, Fengyu
AU - Stajich, Jeffrey M.
AU - Fujiwara, Kenichiro
AU - Scott, Burton L.
AU - Pericak-Vance, Margaret A.
AU - Vance, Jeffery M.
AU - Martin, Eden R.
N1 - Funding Information:
We are grateful to the families who participated in this study. We thank the members of the PD Genetics collaboration—Martha A. Nance, Ray L. Watts, Jean P. Hubble, William C. Koller, Kelly Lyons, Rajesh Pahwa, Matthew B. Stern, Amy Colcher, Bradley C. Hiner, Joseph Jankovic, William G. Ondo, Fred H. Allen Jr., Christopher G. Goetz, Gary W. Small, Donna Masterman, Frank Mastaglia, and Jonathan L. Haines—who contributed families to the study. We thank Yi-Ju Li for helpful discussions. We also thank the personnel at the Center for Human Genetics, Institute for Genome Sciences and Policy, Duke University Medical Center for excellent clinical, technical, and administrative support. This research was supported, in part, by National Institutes of Health Program Project grants 2 P50 NS39764-03 and P01 NS26630. Additional funding was received from National Institute on Aging grant 1R01-AG-20135-01 and GlaxoSmithKline. Joelle M. van der Walt is supported by a postdoctoral fellowship award from the American Parkinson’s Disease Association.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/6
Y1 - 2004/6
N2 - The pathogenic process responsible for the loss of dopaminergic neurons within the substantia nigra of patients with Parkinson disease (PD) is poorly understood. Current research supports the involvement of fibroblast growth factor (FGF20) in the survival of dopaminergic cells. FGF20 is a neurotrophic factor that is preferentially expressed within the substantia nigra of rat brain. The human homologue has been mapped to 8p21.3-8p22, which is within an area of PD linkage revealed through our published genomic screen. To test whether FGF20 influences risk of PD, we genotyped five single-nucleotide polymorphisms (SNPs) lying within the FGF20 gene, in a large family study. We analyzed our sample (644 families) through use of the pedigree disequilibrium test (PDT), the genotype PDT, the multilocus-genotype PDT, and the family-based association test to assess association between risk of PD and alleles, genotypes, multilocus genotypes, and haplotypes. We discovered a highly significant association of PD with one intronic SNP, rs1989754 (P = .0006), and two SNPs, rs1721100 (P = .02) and ss20399075 (P = .0008), located in the 3′ regulatory region in our overall sample. Furthermore, we detected a haplotype (A-G-C-C-T) that is positively associated with risk of PD (P = .0003), whereas a second haplotype (A-G-G-G-C) was found to be negatively associated with risk of PD (P = .0009). Our results strongly support FGF20 as a risk factor for PD.
AB - The pathogenic process responsible for the loss of dopaminergic neurons within the substantia nigra of patients with Parkinson disease (PD) is poorly understood. Current research supports the involvement of fibroblast growth factor (FGF20) in the survival of dopaminergic cells. FGF20 is a neurotrophic factor that is preferentially expressed within the substantia nigra of rat brain. The human homologue has been mapped to 8p21.3-8p22, which is within an area of PD linkage revealed through our published genomic screen. To test whether FGF20 influences risk of PD, we genotyped five single-nucleotide polymorphisms (SNPs) lying within the FGF20 gene, in a large family study. We analyzed our sample (644 families) through use of the pedigree disequilibrium test (PDT), the genotype PDT, the multilocus-genotype PDT, and the family-based association test to assess association between risk of PD and alleles, genotypes, multilocus genotypes, and haplotypes. We discovered a highly significant association of PD with one intronic SNP, rs1989754 (P = .0006), and two SNPs, rs1721100 (P = .02) and ss20399075 (P = .0008), located in the 3′ regulatory region in our overall sample. Furthermore, we detected a haplotype (A-G-C-C-T) that is positively associated with risk of PD (P = .0003), whereas a second haplotype (A-G-G-G-C) was found to be negatively associated with risk of PD (P = .0009). Our results strongly support FGF20 as a risk factor for PD.
UR - http://www.scopus.com/inward/record.url?scp=2442642599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442642599&partnerID=8YFLogxK
U2 - 10.1086/421052
DO - 10.1086/421052
M3 - Article
C2 - 15122513
AN - SCOPUS:2442642599
VL - 74
SP - 1121
EP - 1127
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
SN - 0002-9297
IS - 6
ER -